488 related articles for article (PubMed ID: 28183140)
1. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
2. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN; Chen D; Piccart M; Rugo HS; Burris HA; Pritchard KI; Campone M; Noguchi S; Perez AT; Deleu I; Shtivelband M; Masuda N; Dakhil S; Anderson I; Robinson DM; He W; Garg A; McDonald ER; Bitter H; Huang A; Taran T; Bachelot T; Lebrun F; Lebwohl D; Baselga J
J Clin Oncol; 2016 Feb; 34(5):419-26. PubMed ID: 26503204
[TBL] [Abstract][Full Text] [Related]
3. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
5. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F; Hurvitz S; Fasolo A; Tseng LM; Jerusalem G; Wilks S; O'Regan R; Isaacs C; Toi M; Burris H; He W; Robinson D; Riester M; Taran T; Chen D; Slamon D
J Clin Oncol; 2016 Jun; 34(18):2115-24. PubMed ID: 27091708
[TBL] [Abstract][Full Text] [Related]
6. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO
Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
[TBL] [Abstract][Full Text] [Related]
11. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
[TBL] [Abstract][Full Text] [Related]
12. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
13. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
14. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Sim SH; Yang HN; Jeon SY; Lee KS; Park IH
Sci Rep; 2021 Mar; 11(1):5566. PubMed ID: 33692409
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
19. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
[TBL] [Abstract][Full Text] [Related]
20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
